Scholarlink

Background <p>Conventional epidemiological studies have reported inconsistent results regarding the potential adverse effects of long-term use of antihypertensive drugs on cancer risk. Nevertheless, evidence of their impact on pancreatic cancer risk is limited and deserves further elucidation.</p> Methods <p>We selected genetic variants from the genes encoding the target proteins (angiotensin-converting enzyme, beta-1 adrenergic receptor, and solute carrier family 12 member 3) of the examined antihypertensive drugs as instruments based on expression quantitative trait loci (eQTL) studies. Genetic summary statistics of blood pressure and pancreatic cancer were obtained from genome-wide association studies (GWASs) in Europeans and East Asians. Inverse-variance weight and MR-Egger methods were employed to estimate the effect of genetic variations in the drug targets on pancreatic cancer risk, and meta-analysis was used to combine the results from 3 independent datasets. Positive control analysis was conducted by using Wald ratio test to justify the genetic instruments of the drug by demonstrating the expected effect on the blood pressure which has an established causal relationship with the drug of interest.</p> Results <p>Genetically proxied ACEIs were associated with lower pancreatic risk (OR = 0.506, 95% CI: 0.284–0.901, <i>P</i> = 0.021; OR = 0.265, 95% CI: 0.094–0.751, <i>P</i> = 0.012; OR = 0.236, 95% CI:0.078–0.712, <i>P</i> = 0.010, respectively) in 3 independent datasets and the combined results were validated in a meta-analysis using a random effects model (OR = 0.37, 95% CI: 0.22–0.64, <i>P</i> &lt; 0.01) or fixed effects model (OR = 0.39, 95% CI: 0.25–0.62, <i>P</i> &lt; 0.01). Other drug targets did not show consistent significant associations with pancreatic cancer risk in all 3 independent datasets.</p> Conclusions <p>Our study indicated that genetically proxied therapeutic inhibition of ACE was associated with a lower risk of pancreatic cancer, which may have translational potential in clinical practice. However, further long-term randomized controlled trials and observational studies are needed to clarify the effect of ACEIs on the pancreatic cancer risk.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Genetically proxied therapeutic inhibition of antihypertensive drug targets and risk of pancreatic cancer: a mendelian randomization analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月14日

查看全文
  • Zehui Yao,
  • Dailei Qin,
  • Jianzhong Cao,
  • Chun Gao,
  • Pu Xi,
  • Shengping Li,
  • Ran Wei

摘要

Background

Conventional epidemiological studies have reported inconsistent results regarding the potential adverse effects of long-term use of antihypertensive drugs on cancer risk. Nevertheless, evidence of their impact on pancreatic cancer risk is limited and deserves further elucidation.

Methods

We selected genetic variants from the genes encoding the target proteins (angiotensin-converting enzyme, beta-1 adrenergic receptor, and solute carrier family 12 member 3) of the examined antihypertensive drugs as instruments based on expression quantitative trait loci (eQTL) studies. Genetic summary statistics of blood pressure and pancreatic cancer were obtained from genome-wide association studies (GWASs) in Europeans and East Asians. Inverse-variance weight and MR-Egger methods were employed to estimate the effect of genetic variations in the drug targets on pancreatic cancer risk, and meta-analysis was used to combine the results from 3 independent datasets. Positive control analysis was conducted by using Wald ratio test to justify the genetic instruments of the drug by demonstrating the expected effect on the blood pressure which has an established causal relationship with the drug of interest.

Results

Genetically proxied ACEIs were associated with lower pancreatic risk (OR = 0.506, 95% CI: 0.284–0.901, P = 0.021; OR = 0.265, 95% CI: 0.094–0.751, P = 0.012; OR = 0.236, 95% CI:0.078–0.712, P = 0.010, respectively) in 3 independent datasets and the combined results were validated in a meta-analysis using a random effects model (OR = 0.37, 95% CI: 0.22–0.64, P < 0.01) or fixed effects model (OR = 0.39, 95% CI: 0.25–0.62, P < 0.01). Other drug targets did not show consistent significant associations with pancreatic cancer risk in all 3 independent datasets.

Conclusions

Our study indicated that genetically proxied therapeutic inhibition of ACE was associated with a lower risk of pancreatic cancer, which may have translational potential in clinical practice. However, further long-term randomized controlled trials and observational studies are needed to clarify the effect of ACEIs on the pancreatic cancer risk.